Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Current Assets (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Current Assets for 4 consecutive years, with $97.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets rose 42.62% to $97.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $97.8 million, a 42.62% increase, with the full-year FY2024 number at $69.2 million, down 22.38% from a year prior.
  • Current Assets was $97.8 million for Q3 2025 at Orchestra BioMed Holdings, up from $35.9 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $129.9 million in Q1 2023 to a low of $872555.0 in Q3 2022.
  • A 4-year average of $66.9 million and a median of $69.2 million in 2024 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: skyrocketed 12528.32% in 2023, then plummeted 46.03% in 2025.
  • Orchestra BioMed Holdings' Current Assets stood at $84.7 million in 2022, then rose by 5.22% to $89.1 million in 2023, then dropped by 22.38% to $69.2 million in 2024, then soared by 41.34% to $97.8 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Current Assets are $97.8 million (Q3 2025), $35.9 million (Q2 2025), and $51.9 million (Q1 2025).